Top

Published in:

01-01-2011 | Brief Report

Individual responses to chemotherapy-induced oxidative stress

Authors: Dora Il’yasova, Kelly Kennedy, Ivan Spasojevic, Frances Wang, Adviye A. Tolun, Karel Base, Sarah P. Young, P. Kelly Marcom, Jeffrey Marks, David S. Millington, Mark W. Dewhirst

Published in: Breast Cancer Research and Treatment | Issue 2/2011

Abstract

Differences in redox homeostatic control between cancer patients may underlie predisposition to drug resistance and toxicities. To evaluate interindividual differences in redox response among newly diagnosed breast cancer patients undergoing standard chemotherapy, urine samples were collected before (T0), and at 1 (T1) and 24 h (T24) after chemotherapy administration. Oxidative status was assessed by urinary levels of allantoin and four F2-isoprostanes, quantified by LC–MS/MS. In all subjects, biomarker levels increased at T1 and returned to baseline at T24. Analyzing individual responses, two patterns were revealed: 10 subjects showed uniform increases of biomarker levels at T1 (“increase” pattern) and 8 subjects showed mixed (increase/unchanged/decrease) responses for different biomarkers (“mixed” pattern). The increase-pattern group had lower pre-treatment (T0) levels of the biomarkers and showed a sharp increase at T1 (64–141%) with a subsequent decrease at T24. The mixed-pattern group had higher pre-treatment biomarker levels and showed no change in biomarkers either at T1 or at T24. These findings indicate that there may be at least two distinct redox phenotypes with different homeostatic mechanisms balancing oxidative stress in humans. Recognizing redox phenotypes in human populations may lead to more precise assessment of health risks and benefits associated with individual redox make-up, and may also help to identify cancer patients who are especially susceptible to drug resistance and/or drug toxicity.

Doroshow JH (2006) Redox modulation of chemotherapy-induced tumor cell killing and normal tissue toxicity. J Natl Cancer Inst 98:223–225CrossRefPubMed

Halliwell B, Whiteman M (2004) Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? Br J Pharmacol 142:231–255CrossRefPubMed

Block G, Dietrich M, Norkus EP, Morrow JD, Hudes M, Caan B, Packer L (2002) Factors associated with oxidative stress in human populations. Am J Epidemiol 156:274–285CrossRefPubMed

Halliwell B, Gutteridge JMC (2007) Free radicals in biology and medicine. Oxford University Press, Oxford

Droge W (2002) Free radicals in the physiological control of cell function. Physiol Rev 82:47–95PubMed

Il’yasova D, Spasojevich I, Wang F, Tolun AA, Base K, Young SP, Marcom PK, Marks J, Mixon G, Di Giulio R, Millington DS (2010) Urinary biomarkers of oxidative status in a clinical model of oxidative assault. Cancer Epidemiol Biomarkers Prev 19(6):1506–1510. doi:10.1158/1055-9965.EPI-10-0211 CrossRefPubMed

Il’yasova D, Mixon G, Wang F, Marcom PK, Marks J, Spasojevich I, Craft N, Arredondo F, DiGiulio R (2009) Markers of oxidative status in a clinical model of oxidative assault: a pilot study in human blood following doxorubicin administration. Biomarkers 14:321–325CrossRefPubMed

Tolun AA, Zhang H, Il’yasova D, Sztbray J, Young SP, Millington DS (2010) Allantoin in human urine quantified by ultra-performance liquid chromatography-tandem mass spectrometry. Anal Biochem 402:191–193CrossRefPubMed

Stowe DF, Camara AK (2009) Mitochondrial reactive oxygen species production in excitable cells: modulators of mitochondrial and cell function. Antioxid Redox Signal 11:1373–1414CrossRefPubMed

10.

Brookes PS (2005) Mitochondrial H(+) leak and ROS generation: an odd couple. Free Radic Biol Med 38:12–23CrossRefPubMed

11.

Bedard K, Krause KH (2007) The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 87:245–313CrossRefPubMed

12.

Santos CX, Tanaka LY, Wosniak J, Laurindo FR (2009) Mechanisms and implications of reactive oxygen species generation during the unfolded protein response: roles of endoplasmic reticulum oxidoreductases, mitochondrial electron transport, and NADPH oxidase. Antioxid Redox Signal 11:2409–2427CrossRefPubMed

13.

Wosniak J Jr, Santos CX, Kowaltowski AJ, Laurindo FR (2009) Cross-talk between mitochondria and NADPH oxidase: effects of mild mitochondrial dysfunction on angiotensin II-mediated increase in Nox isoform expression and activity in vascular smooth muscle cells. Antioxid Redox Signal 11:1265–1278CrossRefPubMed

14.

Lopes LR, Dagher MC, Gutierrez A, Young B, Bouin AP, Fuchs A, Babior BM (2004) Phosphorylated p40PHOX as a negative regulator of NADPH oxidase. Biochemistry 43:3723–3730CrossRefPubMed

15.

Desouki MM, Kulawiec M, Bansal S, Das GM, Singh KK (2005) Cross talk between mitochondria and superoxide generating NADPH oxidase in breast and ovarian tumors. Cancer Biol Ther 4:1367–1373CrossRefPubMed

16.

Fogarty S, Hardie DG (2010) Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim Biophys Acta 1804:581–591PubMed

17.

Lin J, Handschin C, Spiegelman BM (2005) Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab 1:361–370CrossRefPubMed

18.

Chan SH, Wu CA, Wu KL, Ho YH, Chang AY, Chan JY (2009) Transcriptional upregulation of mitochondrial uncoupling protein 2 protects against oxidative stress-associated neurogenic hypertension. Circ Res 105:886–896CrossRefPubMed

19.

Handschin C (2009) Peroxisome proliferator-activated receptor-gamma coactivator-1alpha in muscle links metabolism to inflammation. Clin Exp Pharmacol Physiol 36:1139–1143CrossRefPubMed

20.

Kahn BB, Alquier T, Carling D, Hardie DG (2005) AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1:15–25CrossRefPubMed

21.

Lombardi A, de Lange P, Silvestri E, Busiello RA, Lanni A, Goglia F, Moreno M (2009) 3, 5-Diiodo-L-thyronine rapidly enhances mitochondrial fatty acid oxidation rate and thermogenesis in rat skeletal muscle: AMP-activated protein kinase involvement. Am J Physiol Endocrinol Metab 296(3):E497–E502CrossRefPubMed

22.

Il’yasova D, Morrow JD, Wagenknecht LE (2005) Urinary F2-isoprostanes are not associated with increased risk of type 2 diabetes. Obes Res 13:1638–1644CrossRefPubMed

23.

Olmos Y, Valle I, Borniquel S, Tierrez A, Soria E, Lamas S, Monsalve M (2009) Mutual dependence of Foxo3a and PGC-1alpha in the induction of oxidative stress genes. J Biol Chem 284:14476–14484CrossRefPubMed

24.

St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, JSger S, Handschin C, Zheng K, Lin J, Yang W, Simon DK, Bachoo R, Spiegelman BM (2006) Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 127:397–408CrossRefPubMed

25.

Kong X, Fan H, Liu X, Wang R, Liang J, Gupta N, Chen Y, Fang F, Chang Y (2009) Peroxisome proliferator-activated receptor gamma coactivator-1alpha enhances antiproliferative activity of 5’-deoxy-5-fluorouridine in cancer cells through induction of uridine phosphorylase. Mol Pharmacol 76:854–860CrossRefPubMed

26.

Wojnowski L, Kulle B, Schirmer M, Schluter G, Schmidt A, Rosenberger A, Vonhof S, Bickeboller H, Toliat MR, Suk EK, Tzvetkov M, Kruger A, Seifert S, Kloess M, Hahn H, Loeffler M, Nurnberg P, Pfreundschuh M, Trumper L, Brockmoller J, Hasenfuss G (2005) NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 112:3754–3762CrossRefPubMed

27.

Hoffmann M, Schirmer MA, Tzvetkov MV, Kreuz M, Ziepert M, Wojnowski L, Kube D, Pfreundschuh M, Trumper L, Loeffler M, Brockmoller J (2010) A functional polymorphism in the NAD(P)H oxidase subunit CYBA is related to gene expression, enzyme activity, and outcome in non-Hodgkin lymphoma. Cancer Res 70:2328–2338CrossRefPubMed

28.

Landriscina M, Maddalena F, Laudiero G, Esposito F (2009) Adaptation to oxidative stress, chemoresistance, and cell survival. Antioxid Redox Signal 11:2701–2716CrossRefPubMed

29.

Pennington JD, Wang TJ, Nguyen P, Sun L, Bisht K, Smart D, Gius D (2005) Redox-sensitive signaling factors as a novel molecular targets for cancer therapy 1. Drug Resist Updat 8:322–330CrossRefPubMed

30.

Yokomizo A, Ono M, Nanri H, Makino Y, Ohga T, Wada M, Okamoto T, Yodoi J, Kuwano M, Kohno K (1995) Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide 1. Cancer Res 55:4293–4296PubMed

31.

Mitchell JB, Russo A (1987) The role of glutathione in radiation and drug induced cytotoxicity 1. Br J Cancer Suppl 8:96–104PubMed

Title: Individual responses to chemotherapy-induced oxidative stress
Authors: Dora Il’yasova
Kelly Kennedy
Ivan Spasojevic
Frances Wang
Adviye A. Tolun
Karel Base
Sarah P. Young
P. Kelly Marcom
Jeffrey Marks
David S. Millington
Mark W. Dewhirst
Publication date: 01-01-2011
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-010-1158-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2011

Lack of association between ATM C.1066-6T > G mutation and breast cancer risk: a meta-analysis of 8,831 cases and 4,957 controls

Association between two polymorphisms of ABCB1 and breast cancer risk in the current studies: a meta-analysis

Relationship between diabetes and risk of second primary contralateral breast cancer

Polymorphisms of the nuclear receptor pregnane X receptor and organic anion transporter polypeptides 1A2, 1B1, 1B3, and 2B1 are not associated with breast cancer risk

The association between two polymorphisms in pre-miRNAs and breast cancer risk: a meta-analysis

No significant association results obtained from significant association evidence: the ongoing uncertainty of TP53 codon 72 polymorphism and breast cancer risk

Keynote webinar | Spotlight on antibody–drug conjugates in cancer